-
1
-
-
0036829649
-
National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C, 10-12 June 2002
-
National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C, 10-12 June 2002. Hepatology, 2002, 36: S3-20.
-
(2002)
Hepatology
, vol.36
-
-
-
2
-
-
12444346656
-
Natural history of initially mild chronic hepatitis C
-
ALBERTI A., BENVEGNÙ L., BOCCATO S., FERRARI A., SEBASTIANI G. Natural history of initially mild chronic hepatitis C. Dig. Liver Dis., 2004, 36: 646-54.
-
(2004)
Dig. Liver Dis.
, vol.36
, pp. 646-654
-
-
Alberti, A.1
Benvegnù, L.2
Boccato, S.3
Ferrari, A.4
Sebastiani, G.5
-
3
-
-
7244260730
-
Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy
-
WEISSENBORN K., KRAUSE J., BOKEMEYER M., HECKER H., SCHULER A., ENNEN J.C., AHL B., MANNS M.P., BOKER K.W. Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J. Hepatol., 2004, 41: 845-51.
-
(2004)
J. Hepatol.
, vol.41
, pp. 845-851
-
-
Weissenborn, K.1
Krause, J.2
Bokemeyer, M.3
Hecker, H.4
Schuler, A.5
Ennen, J.C.6
Ahl, B.7
Manns, M.P.8
Boker, K.W.9
-
4
-
-
0037126675
-
Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection
-
ALBERTI A., NOVENTA E, BENVEGNÙ L., BOCCATO S., GATTA A. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann. Intern. Med., 2002, 137: 961-964.
-
(2002)
Ann. Intern. Med.
, vol.137
, pp. 961-964
-
-
Alberti, A.1
Noventa, E.2
Benvegnù, L.3
Boccato, S.4
Gatta, A.5
-
5
-
-
1942467895
-
Normal serum aminotransferase concentration and risk of mortality from liver diseases: Prospective cohort study
-
KIM H.C., NAM C.M., JEE S.H., HAN K.H., OH D.K., SUH I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. Br. Med. J., 2004, 328: 983.
-
(2004)
Br. Med. J.
, vol.328
, pp. 983
-
-
Kim, H.C.1
Nam, C.M.2
Jee, S.H.3
Han, K.H.4
Oh, D.K.5
Suh, I.6
-
6
-
-
0037008087
-
Updated definitions of healthy ranges for serum alanine aminotransferase levels
-
PRATI D., TAIOLI E., ZANELLA A., DELLA TORRE E., BUTELLI S., DE VECCHIO E., VIANELLO L., ZANUSO F., MOZZI F, MILANI S., CONTE D., COLOMBO M., SIRCHIA G. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann. Intern. Med., 2002, 137: 1-10.
-
(2002)
Ann. Intern. Med.
, vol.137
, pp. 1-10
-
-
Prati, D.1
Taioli, E.2
Zanella, A.3
Della Torre, E.4
Butelli, S.5
De Vecchio, E.6
Vianello, L.7
Zanuso, F.8
Mozzi, F.9
Milani, S.10
Conte, D.11
Colombo, M.12
Sirchia, G.13
-
7
-
-
12444261843
-
Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanineaminotransferase levels
-
ALBERTI A. Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanineaminotransferase levels. J. Hepatol., 2005, 42: 266-74.
-
(2005)
J. Hepatol.
, vol.42
, pp. 266-274
-
-
Alberti, A.1
-
8
-
-
9644262441
-
Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels
-
ZEUZEM S., DIAGO M., GANE E., REDDY K.R., POCKROS P., PRATI D., SHIFFMAN M., FARCI P., GITLIN N., O'BRIEN C.B., LAMOUR F, LARDELLI P., PEGASYS Study NR16071 Investigator Group. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology, 2004, 127: 1724-32.
-
(2004)
Gastroenterology
, vol.127
, pp. 1724-1732
-
-
Zeuzem, S.1
Diago, M.2
Gane, E.3
Reddy, K.R.4
Pockros, P.5
Prati, D.6
Shiffman, M.7
Farci, P.8
Gitlin, N.9
O'Brien, C.B.10
Lamour, F.11
Lardelli, P.12
-
9
-
-
0037371363
-
Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients
-
ROSSI E., ADAMS L., PRINS A., BULSARA M., DE BOER B., GARAS G., MACQUILLAN G., SPEERS D., JEFFREY G. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin. Chem., 2003, 49: 450-4.
-
(2003)
Clin. Chem.
, vol.49
, pp. 450-454
-
-
Rossi, E.1
Adams, L.2
Prins, A.3
Bulsara, M.4
De Boer, B.5
Garas, G.6
Macquillan, G.7
Speers, D.8
Jeffrey, G.9
-
10
-
-
1942454310
-
Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics
-
CALLEWAERT N., VAN VLIERBERGHE H., VAN HECKE A., LAROY W., DELANGHE J., CONTRERAS R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat. Med., 2004, 10: 429-34.
-
(2004)
Nat. Med.
, vol.10
, pp. 429-434
-
-
Callewaert, N.1
Van Vlierberghe, H.2
Van Hecke, A.3
Laroy, W.4
Delanghe, J.5
Contreras, R.6
-
11
-
-
1842479859
-
Diagnosis, management and treatment of hepatitis C
-
STRADER D.B., WRIGHT T., THOMAS D.L., SEEFF L.B. Diagnosis, management and treatment of hepatitis C. Hepatology, 2004, 39: 1147-1171.
-
(2004)
Hepatology
, vol.39
, pp. 1147-1171
-
-
Strader, D.B.1
Wright, T.2
Thomas, D.L.3
Seeff, L.B.4
-
12
-
-
0036829652
-
Fibrosis and disease progression in hepatitis C
-
MARCELLIN P., ASSELAH T., BOYER N. Fibrosis and disease progression in hepatitis C. Hepatology, 2002, 36: S47-S56.
-
(2002)
Hepatology
, vol.36
-
-
Marcellin, P.1
Asselah, T.2
Boyer, N.3
-
13
-
-
0037219481
-
Progression of fibrosis in chronic hepatitis C
-
GHANY M.G., KLEINER D.E., ALTER H., DOO E., KHOKAR F., PROMRAT K., HERION D., PARK Y., LIANG T.J., HOOFNAGLE J.H. Progression of fibrosis in chronic hepatitis C. Gastroenterology, 2003, 124: 97-104.
-
(2003)
Gastroenterology
, vol.124
, pp. 97-104
-
-
Ghany, M.G.1
Kleiner, D.E.2
Alter, H.3
Doo, E.4
Khokar, F.5
Promrat, K.6
Herion, D.7
Park, Y.8
Liang, T.J.9
Hoofnagle, J.H.10
-
14
-
-
0037383495
-
A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase
-
HUI C.K., BELAYE T., MONTEGRANDE K., WRIGHT T.L. A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. J. Hepatol., 2003, 38: 511-517.
-
(2003)
J. Hepatol.
, vol.38
, pp. 511-517
-
-
Hui, C.K.1
Belaye, T.2
Montegrande, K.3
Wright, T.L.4
-
15
-
-
0038352047
-
Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population
-
SALOMON J.A., WEINSTEIN M.C., HAMMITT J.K., GOLDIE S.J. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. J. Am. Med. Assoc., 2003, 290: 228-237.
-
(2003)
J. Am. Med. Assoc.
, vol.290
, pp. 228-237
-
-
Salomon, J.A.1
Weinstein, M.C.2
Hammitt, J.K.3
Goldie, S.J.4
-
16
-
-
0035934568
-
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial
-
MANNS M.P., MCHUTCHISON J.G., GORDON S.C., RUSTGI V.K., SHIFFMAN M., REINDOLLAR R. GOODMAN Z.D., KOURY K., LING M., ALBRECHT J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet, 2001, 358: 958-965.
-
(2001)
Lancet
, vol.358
, pp. 958-965
-
-
Manns, M.P.1
Mchutchison, J.G.2
Gordon, S.C.3
Rustgi, V.K.4
Shiffman, M.5
Reindollar, R.6
Goodman, Z.D.7
Koury, K.8
Ling, M.9
Albrecht, J.K.10
-
17
-
-
0037179698
-
Combination of peginterferon alfa-2a plus ribavirin in patients with chronic hepatitis C virus infection
-
FRIED M.W., SHIFFMAN M.L., REDDY K.R., SMITH C., MARINOS G., GONCALES FR. JR. HAUSSINGER D., DIAGO M., CAROSI G., DHUMEAUX D., CRAXI A., LIN A., HOFFMAN J., YU J. Combination of peginterferon alfa-2a plus ribavirin in patients with chronic hepatitis C virus infection. N. Engl. J. Med., 2002, 347: 975-982.
-
(2002)
N. Engl. J. Med.
, vol.347
, pp. 975-982
-
-
Fried, M.W.1
Shiffman, M.L.2
Reddy, K.R.3
Smith, C.4
Marinos, G.5
Goncales Jr., F.R.6
Haussinger, D.7
Diago, M.8
Carosi, G.9
Dhumeaux, D.10
Craxi, A.11
Lin, A.12
Hoffman, J.13
Yu, J.14
-
18
-
-
2142695339
-
A health economic model to assess the long term effects and cost-effectiveness of PEG IFN α-2a in hepatitis C virus infected patients
-
ANNEMANS L., WARIE H., NECHELPUT M., PERAUX B. A health economic model to assess the long term effects and cost-effectiveness of PEG IFN α-2a in hepatitis C virus infected patients. Acta Gastroenterol. Belg., 2004, 67: 1-8.
-
(2004)
Acta Gastroenterol. Belg.
, vol.67
, pp. 1-8
-
-
Annemans, L.1
Warie, H.2
Nechelput, M.3
Peraux, B.4
-
19
-
-
12244274965
-
Hepatitis C: Screening, treatment and prevention practical guidelines
-
MICHIELSEN P., BRENARD R., BOURGEOIS N., DE GALOCSY CH., DELWAIDE J., HENRION J., HORSMANS Y., NEVENS F., REYNAERT H., ROBAEYS G., SPRENGERS D., VAN VLIERBERGHE H., Steering Committee Belgian Association for the Study of the Liver. Hepatitis C: screening, treatment and prevention practical guidelines. Acta Gastroenterol. Belg., 2003, 66: 15-9.
-
(2003)
Acta Gastroenterol. Belg.
, vol.66
, pp. 15-19
-
-
Michielsen, P.1
Brenard, R.2
Bourgeois, N.3
De Galocsy, C.H.4
Delwaide, J.5
Henrion, J.6
Horsmans, Y.7
Nevens, F.8
Reynaert, H.9
Robaeys, G.10
Sprengers, D.11
Van Vlierberghe, H.12
-
20
-
-
26944472957
-
Cost-effectiveness of interferon α or peginterferon β, with ribavirin for histologically mild chronic hepatitis C
-
Epub June 30, 2005
-
GRIEVE R., ROBERTS J., WRIGHT M., SWEETING M., DEANGELIS D., ROSENBERG W., BASSENDINE M., MAIN J., THOMAS H. Cost-effectiveness of interferon α or peginterferon β, with ribavirin for histologically mild chronic hepatitis C. Gut, 2005 (Epub June 30, 2005).
-
(2005)
Gut
-
-
Grieve, R.1
Roberts, J.2
Wright, M.3
Sweeting, M.4
Deangelis, D.5
Rosenberg, W.6
Bassendine, M.7
Main, J.8
Thomas, H.9
|